Revision History

A Phase 3 trial of daraxonrasib, a first-in-class RAS(ON) inhibitor made by Revolution Medicines, nearly doubled median overall survival in previously treated metastatic pancreatic cancer (13.2 vs. 6.7 months), marking the first targeted therapy to show a significant survival benefit against KRAS-driven pancreatic tumors. While the results have energized a field that has seen little progress in decades, questions about resistance, long-term durability, patient access, pricing, and the representativeness of the trial population temper the enthusiasm.